Paxillin and Androgens in the Regulation of Ovarian Follicle Development
Project Number5K08HD107134-03
Former Number1K08HD107134-01
Contact PI/Project LeaderASTAPOVA, OLGA
Awardee OrganizationUNIVERSITY OF ROCHESTER
Description
Abstract Text
1 Project Summary / Abstract
2 This career development project will provide a path for a highly qualified candidate with a combined MD/PhD
3 degree into a career as an independent investigator in reproductive science. Female infertility due to disorders
4 of androgen excess or insufficiency is a growing problem in the U.S. and worldwide with high mental and financial
5 costs. Androgen imbalance is implicated in polycystic ovary syndrome (PCOS) and diminished ovarian reserve
6 (DOR); however, while the phenotypic effects of androgen activity in the ovary are significant, little is known
7 about the underlying molecular pathways. This proposal aims to elucidate the mechanisms of androgen actions
8 in ovarian follicle growth and atresia, which are disordered in PCOS and DOR. The research direction stems
9 from the recent finding by the candidate that the androgen-regulated mRNA transcriptome in ovarian granulosa
10 cells is surprisingly small, and focuses on non-coding RNA regulation by androgens in granulosa cells. The
11 proposal also builds on prior studies of paxillin as a mediator of androgen signaling in prostate cancer. The role
12 of paxillin as a regulator of the androgen receptor expression is assessed for the first time in granulosa cells in
13 this proposal. The effects of paxillin loss in granulosa cells on follicular development and fertility will be examined
14 in a granulosa cell-specific knockout mouse model. The molecular mechanisms involving microRNA regulation
15 by androgens in granulosa cells will be studied in cultured mouse and human cells. The hypothesis is that
16 androgen effects in granulosa cells are mediated in large part by microRNAs, and are enhanced by paxillin. The
17 project has the potential to suggest novel therapeutic avenues for PCOS, a disease with sub-optimal
18 management options. The training plan capitalizes on the applicant’s strong research background and long-
19 standing interest in female fertility. She aims to build on her technical skills, develop as a leader and a member
20 of the scientific community, and transition to independence in research. The mentor is a physician-scientist who
21 is a world expert in paxillin and androgen signaling, mouse genetics and ovarian biology with a long track record
22 of mentoring successful trainees. The training will take place in a highly collaborative environment where
23 expertise in reproductive research techniques is abundant. The applicant has assembled an advisory committee
24 comprised of world experts in ovarian biology, paxillin, steroid signaling, and microRNA sequencing. She will
25 take advantage of University-sponsored courses in translational research methods, leadership and professional
26 development, as well as research seminars, national meetings and one-on-one instruction. At the end of this
27 project, she plans to write several first-author publications, run a lab independently, mentor a graduate student
28 and apply for an R-01 grant.
Public Health Relevance Statement
Project Narrative
Female infertility due to disorders of androgen imbalance, namely polycystic ovary syndrome and ovarian
insufficiency, are a growing public health problem in the U.S. and worldwide. This project aims to delineate the
mechanisms of androgen actions in the ovary, focusing on novel non-coding RNA regulation by androgen
receptor in granulosa cells and the role of cytoplasmic adaptor protein paxillin. The training plan is designed to
groom a young physician-scientist for an independent career in reproductive science, and the findings will
advance our understanding of the molecular mechanisms underlying female fertility.
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
865
DUNS Number
041294109
UEI
F27KDXZMF9Y8
Project Start Date
01-September-2022
Project End Date
31-August-2025
Budget Start Date
01-September-2024
Budget End Date
31-August-2025
Project Funding Information for 2024
Total Funding
$153,203
Direct Costs
$141,855
Indirect Costs
$11,348
Year
Funding IC
FY Total Cost by IC
2024
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$153,203
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5K08HD107134-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K08HD107134-03
Patents
No Patents information available for 5K08HD107134-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K08HD107134-03
Clinical Studies
No Clinical Studies information available for 5K08HD107134-03
News and More
Related News Releases
No news release information available for 5K08HD107134-03
History
No Historical information available for 5K08HD107134-03
Similar Projects
No Similar Projects information available for 5K08HD107134-03